BUZZ-GW Pharmaceuticals Plc: Drug could have potential in autism - Telegraph

Wed, 03rd Dec 2014 20:10

** Cannibis-based drugmaker's U.S.-listed shares up11.11 pct at $76.29, snapping a three-day streak of declines

** Company putting together "building blocks" of a researchprogram to see if a cannabis-based medicine could treat symptomsof autism, CEO told The Telegraph (http://bit.ly/1pUWFCw)

** Physicians treating severely epileptic children with theexperimental drug, epidiolex, saw improvements in behavior andbrain function in patients who also had autism, CEO says

** Stock among top percentage gainers on the Nasdaq

** Up to Tuesday's close, the U.S.-listed shares of thecompany had gained 65 pct this year

Related Shares

More News

3 Feb 2021 12:49

Jazz Pharmaceuticals to buy GW Pharmaceuticals for $7.2bn

(Sharecast News) - Jazz Pharmaceuticals has agreed to buy GW Pharmaceuticals for $7.2bn.

26 Nov 2018 15:49

GW Pharmaceuticals stock flies 4.8% after reporting positive test trial

(Sharecast News) - GW Pharmaceuticals stock rose by 4.8% on Monday after it announced positive test results from new cannabis-based drug trials.

12 Feb 2017 15:06

Sunday newspaper round-up: Inflation, RBS, Brexit defeat, BAE Systems

(ShareCast News) - Higher food and fuel prices drove inflation to a three-year zenith of 2% in January, up from 1.6% in December, with more increases ...

28 Oct 2016 16:24

DIRECTOR DEALINGS: GW Pharmaceuticals Chairman Sells 300,000 Shares

19 Oct 2016 08:20

GW Pharmaceuticals to cancel London listing, keep Nasdaq

(ShareCast News) - GW Pharmaceuticals plans to cancel its shares from trading on AIM on 5 December, with the last day of trading on the 2nd, but will ...

Latest Share Chat